Sanofi CEO Paul Hudson’s latest M&A gambit adds new eczema drug in $1.5B buyout. And he’s steering back into a market maelstrom

Around the same time that Sanofi CEO Paul Hudson was engineering a $3.7 billion buyout of Principia to add a late-stage multiple sclerosis drug to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom